Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients
- PMID: 35935981
- PMCID: PMC9353143
- DOI: 10.3389/fimmu.2022.883886
Sildenafil, a Type-5 Phosphodiesterase Inhibitor, Fails to Reverse Myeloid-Derived Suppressor Cell-Mediated T Cell Suppression in Cells Isolated From Tuberculosis Patients
Abstract
Successful TB treatment is hampered by increasing resistance to the two most effective first-line anti-TB drugs, namely isoniazid and rifampicin, thus innovative therapies focused on host processes, termed host-directed therapies (HDTs), are promising novel approaches for increasing treatment efficacy without inducing drug resistance. We assessed the ability of Sildenafil, a type-5 phosphodiesterase inhibitor, as a repurposed compound, to serve as HDT target, by counteracting the suppressive effects of myeloid-derived suppressor cells (MDSC) obtained from active TB cases on T-cell responsiveness. We confirm that MDSC suppress non-specific T-cell activation. We also show that Sildenafil treatment fails to reverse the MDSC-mediated suppression of T-cell functions measured here, namely activation and proliferation. The impact of Sildenafil treatment on improved immunity, using the concentration tested here, is likely to be minimal, but further identification and development of MDSC-targeting TB host-directed therapies are warranted.
Keywords: Mycobacterium tuberculosis; Sildenafil; host-directed therapies; myeloid-derived suppressor cells; tuberculosis.
Copyright © 2022 Leukes, Malherbe, Hiemstra, Kotze, Roos, Keyser, De Swardt, Gutschmidt, Walzl and du Plessis.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.Front Immunol. 2020 Mar 25;11:451. doi: 10.3389/fimmu.2020.00451. eCollection 2020. Front Immunol. 2020. PMID: 32269568 Free PMC article. Review.
-
Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis.Cell Immunol. 2021 Jun;364:104359. doi: 10.1016/j.cellimm.2021.104359. Epub 2021 Apr 8. Cell Immunol. 2021. PMID: 33865151 Free PMC article.
-
Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.Front Cell Infect Microbiol. 2018 Sep 21;8:332. doi: 10.3389/fcimb.2018.00332. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 30298121 Free PMC article. Review.
-
Immunometabolism of Myeloid-Derived Suppressor Cells: Implications for Mycobacterium tuberculosis Infection and Insights from Tumor Biology.Int J Mol Sci. 2022 Mar 23;23(7):3512. doi: 10.3390/ijms23073512. Int J Mol Sci. 2022. PMID: 35408873 Free PMC article. Review.
-
Circulating Monocyte-Like Myeloid Derived Suppressor Cells and CD16 Positive Monocytes Correlate With Immunological Responsiveness of Tuberculosis Patients.Front Cell Infect Microbiol. 2022 Mar 14;12:841741. doi: 10.3389/fcimb.2022.841741. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35360105 Free PMC article.
Cited by
-
Advances in the study of myeloid-derived suppressor cells in infectious lung diseases.Front Immunol. 2023 Mar 29;14:1125737. doi: 10.3389/fimmu.2023.1125737. eCollection 2023. Front Immunol. 2023. PMID: 37063919 Free PMC article. Review.
-
Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection.Front Immunol. 2023 Jul 20;14:1222911. doi: 10.3389/fimmu.2023.1222911. eCollection 2023. Front Immunol. 2023. PMID: 37545508 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical